Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
Catalyst Pharmaceuticals (Nasdaq: CPRX) has been named among the BioSpace 2025 Best Places to Work, joining 50 other U.S. employers recognized as the most sought-after in the industry. The recognition comes from votes and ratings by thousands of life sciences community members, evaluating companies based on culture, career growth, leadership, and innovation.
The selection process, conducted in 2024, involved nominations in June and voting in August, with over 3,000 life sciences professionals rating organizations on factors including compensation, innovation, career opportunities, leadership, culture, DEI, reputation, and work flexibility. President and CEO Richard J. Daly highlighted the company's commitment to creating an environment that promotes growth, development, and trust while focusing on improving patient care for rare diseases.
Catalyst Pharmaceuticals (Nasdaq: CPRX) è stata nominata tra i Best Places to Work 2025 da BioSpace, unendosi ad altri 50 datori di lavoro statunitensi riconosciuti come i più ambiti del settore. Questo riconoscimento deriva dai voti e dalle valutazioni di migliaia di membri della comunità delle scienze della vita, che hanno valutato le aziende in base alla cultura, alla crescita professionale, alla leadership e all'innovazione.
Il processo di selezione, condotto nel 2024, ha previsto le nomination a giugno e il voto ad agosto, con oltre 3.000 professionisti delle scienze della vita che hanno valutato le organizzazioni su fattori come compenso, innovazione, opportunità di carriera, leadership, cultura, diversità, equità e inclusione, reputazione e flessibilità lavorativa. Il presidente e CEO Richard J. Daly ha sottolineato l'impegno dell'azienda nel creare un ambiente che promuove crescita, sviluppo e fiducia, focalizzandosi nel migliorare l'assistenza ai pazienti affetti da malattie rare.
Catalyst Pharmaceuticals (Nasdaq: CPRX) ha sido nombrada entre los Mejores Lugares para Trabajar 2025 por BioSpace, uniéndose a otros 50 empleadores de EE. UU. reconocidos como los más deseados en la industria. Este reconocimiento proviene de los votos y calificaciones de miles de miembros de la comunidad de ciencias de la vida, quienes evaluaron a las empresas en función de la cultura, el crecimiento profesional, el liderazgo y la innovación.
El proceso de selección, realizado en 2024, incluyó nominaciones en junio y votaciones en agosto, con más de 3.000 profesionales de ciencias de la vida evaluando organizaciones en factores como compensación, innovación, oportunidades de carrera, liderazgo, cultura, diversidad, equidad e inclusión, reputación y flexibilidad laboral. El presidente y CEO Richard J. Daly destacó el compromiso de la empresa en crear un entorno que fomente el crecimiento, el desarrollo y la confianza, al tiempo que se centra en mejorar la atención a pacientes con enfermedades raras.
카탈리스트 제약(Nasdaq: CPRX)는 BioSpace 2025 최고의 근무지 중 하나로 선정되어, 이 부문에서 가장 선호되는 50개의 미국 고용주와 함께하게 되었습니다. 이 인정은 수천 명의 생명과학 커뮤니티 구성원들의 투표와 평가에 의해 이루어졌으며, 기업들은 문화, 경력 성장, 리더십 및 혁신을 기준으로 평가되었습니다.
2024년에 진행된 선정 과정은 6월에 추천이 이루어지고, 8월에 투표가 진행됐으며, 3,000명 이상의 생명과학 전문가들이 보상, 혁신, 경력 기회, 리더십, 문화, 다양성 및 포용성, 평판, 근무 유연성과 같은 요소를 바탕으로 조직을 평가했습니다. 회사의 회장 및 CEO인 리처드 J. 데일리는 환자 치료 개선에 집중하면서 성장, 개발 및 신뢰를 증진하는 환경을 조성하려는 회사의 노력을 강조했습니다.
Catalyst Pharmaceuticals (Nasdaq: CPRX) a été nommée parmi les Meilleurs Lieux de Travail 2025 par BioSpace, rejoignant ainsi 50 autres employeurs américains reconnus comme les plus recherchés dans l'industrie. Cette reconnaissance provient des votes et des évaluations de milliers de membres de la communauté des sciences de la vie, évaluant les entreprises sur la culture, la croissance professionnelle, le leadership et l'innovation.
Le processus de sélection, mené en 2024, a impliqué des nominations en juin et des votes en août, plus de 3 000 professionnels des sciences de la vie ayant noté les organisations sur des facteurs tels que la rémunération, l'innovation, les opportunités de carrière, le leadership, la culture, la diversité, l'équité, la réputation et la flexibilité au travail. Le président et directeur général Richard J. Daly a souligné l'engagement de l'entreprise à créer un environnement qui favorise la croissance, le développement et la confiance, tout en se concentrant sur l'amélioration des soins aux patients atteints de maladies rares.
Catalyst Pharmaceuticals (Nasdaq: CPRX) wurde unter den Besten Arbeitsplätzen 2025 von BioSpace ausgezeichnet und reiht sich somit unter 50 weitere US-Arbeitgeber, die in der Branche als die begehrtesten gelten. Diese Anerkennung basiert auf Stimmen und Bewertungen von Tausenden von Mitgliedern der Lebenswissenschaftsgemeinschaft, die Unternehmen nach Kultur, Karriereentwicklung, Führung und Innovation bewerteten.
Der Auswahlprozess, der 2024 durchgeführt wurde, umfasste Nominierungen im Juni und Abstimmungen im August, wobei über 3.000 Fachleute der Lebenswissenschaften Organisationen anhand von Faktoren wie Vergütung, Innovation, Karrieremöglichkeiten, Führung, Kultur, Diversität, Chancengleichheit, Ruf und Arbeitsflexibilität bewerteten. Präsident und CEO Richard J. Daly betonte das Engagement des Unternehmens, ein Umfeld zu schaffen, das Wachstum, Entwicklung und Vertrauen fördert, während der Schwerpunkt auf der Verbesserung der Patientenversorgung bei seltenen Krankheiten liegt.
- None.
- None.
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community.
“We are honored to be recognized by BioSpace as one of the Best Places to Work in 2025,” said Richard J. Daly, President and Chief Executive Officer. “Our goal has always been to create an environment that fosters growth, development, and trust, while enabling our team members to fulfill their passion for improving patient care. This award celebrates the dedication of our incredible team, and their steadfast, patient-focused approach is making an important impact in addressing unmet needs of those living with rare diseases.”
The BioSpace 2025 Best Places to Work list highlights a company's desirability in the recruitment marketplace, based on votes and ratings from thousands of members of the life sciences community. BioSpace evaluates each organization’s merits with a focus on culture, career growth and development opportunities, leadership, and innovation. Nominations for Best Places to Work were opened in June 2024. Voting was conducted in August 2024. BioSpace reviewed the votes and rankings submitted by over 3,000 life sciences professionals. Respondents were asked to identify their top three most desirable biopharma companies, segmented by large (more than 1,000+ employees) and small (less than 1,000 employees) companies. Respondents were also asked to rate their top choice organization on attributes including compensation, innovation, career growth opportunities, leadership, culture, diversity, equity and inclusion, reputation, and flexibility and remote work.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When was Catalyst Pharmaceuticals (CPRX) named to BioSpace 2025 Best Places to Work?
How many companies were selected alongside Catalyst Pharmaceuticals (CPRX) for BioSpace 2025 Best Places to Work?
What criteria were used to evaluate Catalyst Pharmaceuticals (CPRX) for the BioSpace 2025 award?
How many professionals participated in voting for BioSpace 2025 Best Places to Work, including Catalyst Pharmaceuticals (CPRX)?
